Compare LSBK & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LSBK | CMPX |
|---|---|---|
| Founded | 1891 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 143.2M | 154.9M |
| IPO Year | 2025 | 2020 |
| Metric | LSBK | CMPX |
|---|---|---|
| Price | $18.98 | $0.76 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $5.46 |
| AVG Volume (30 Days) | 16.9K | ★ 3.0M |
| Earning Date | 10-21-2026 | 11-17-2026 |
| Dividend Yield | ★ 1.92% | N/A |
| EPS Growth | ★ 49.23 | N/A |
| EPS | ★ 0.56 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $34.02 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.83 | $0.73 |
| 52 Week High | $19.34 | $6.88 |
| Indicator | LSBK | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 57.83 | 26.13 |
| Support Level | $16.87 | $0.73 |
| Resistance Level | $18.93 | $2.02 |
| Average True Range (ATR) | 0.41 | 0.05 |
| MACD | 0.04 | 0.03 |
| Stochastic Oscillator | 67.46 | 12.83 |
Lake Shore Bancorp Inc operates as a savings and loan holding company. The bank's business consists of attracting retail deposits from the general public in the areas surrounding its branch offices and investing those deposits, together with funds generated from operations, in commercial real estate loans, one-to-four family residential mortgage loans, home equity lines of credit, and, to a lesser extent, commercial business loans, consumer loans, and investment securities. Its revenues are principally derived from interest earned on loans and investment securities.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.